Christopoulou Maria Elpida, Panteli Lilia S, Moisidis John A, Christopoulos Ioannis A, Kasimeri Maria Eleni, Tryphonidou Amalia S, Christopoulos Antonios I
Asthma Clinics, Primary Care Clinics for Asthma, Allergy & Respiratory Health Athens, Patras, Kalavryta, Greece.
Clinic of Pneumology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
J Asthma Allergy. 2025 Jun 2;18:891-902. doi: 10.2147/JAA.S517194. eCollection 2025.
OM-85 is a well-characterized bacterial lysate with antiviral properties, enhancement of airway epithelial barrier function, and tolerance induction. However, real-world evidence is needed to evaluate its effectiveness as an add-on therapy in patients with allergic asthma.
This retrospective cohort study analyzed medical records of 137 adults with moderate to severe allergic asthma over 12 months. Patients receiving standard of care (SoC) asthma therapy alone (GINA step 4, n = 67) were compared to those on SoC+OM-85 (n = 70). All symptom episodes (CEPs) indicative of respiratory tract infections (RTIs) were recorded, and a 3-scale mean severity index (mSI) was calculated. Propensity score weighting was used for Poisson and linear regression analyses.
Patients on OM-85 demonstrated significant reductions in the number of CEPs (60%), asthma exacerbations (71%), unscheduled visits (72%), oral corticosteroid courses (73%), and antibiotic cycles (67%). The mSI was 1.15 points lower in the OM-85 group (p < 0.001).
OM-85 as an add-on to standard asthma therapy significantly reduced RTI-related episodes, exacerbations, and healthcare utilization while lowering symptom severity in adults with allergic asthma.
OM-85是一种特性明确的细菌裂解物，具有抗病毒特性、增强气道上皮屏障功能以及诱导耐受性。然而，需要真实世界的证据来评估其作为过敏性哮喘患者附加治疗的有效性。
这项回顾性队列研究分析了137例中度至重度过敏性哮喘成人患者12个月的病历。将仅接受哮喘标准治疗（SoC）（全球哮喘防治创议第4步，n = 67）的患者与接受SoC+OM-85治疗（n = 70）的患者进行比较。记录所有表明呼吸道感染（RTI）的症状发作（CEP），并计算3级平均严重程度指数（mSI）。倾向评分加权用于泊松回归和线性回归分析。
接受OM-85治疗的患者在CEP数量（60%）、哮喘加重次数（71%）、非计划就诊次数（72%）、口服糖皮质激素疗程（73%）和抗生素使用周期（67%）方面均有显著减少。OM-85组的mSI低1.15分（p < 0.001）。
OM-85作为标准哮喘治疗的附加药物，可显著减少与RTI相关的发作、加重次数以及医疗资源利用，同时降低过敏性哮喘成人患者的症状严重程度。
